The text starts here.

CHAIRMAN'S MESSAGE

Eisai (Liaoning) Pharmaceutical Company is a foreign pharmaceutical company solely invested by Eisai Co., Ltd.


Eisai Co., Ltd. , headquartered in Tokyo Japan, is a multinational company mainly focuses on R&D. Sales revenue of Fiscal Year 2015 of Eisai Co., Ltd. reached 547.9 billion JPY. There had been a long history of communication between Eisai Co., Ltd. and China’s medical industry. Peking University Health Science Center (PUHSC) started communication with Eisai in 1972, and since when, Eisai had been supporting Sino-Japan academic communication among famous medical universities. As acknowledgement of Eisai’s contribution, Mr. Yuji Naito, the late Chairman of Eisai Co., Ltd., was invited to visit China as one of the first group of leading listed companies in Japan after normalization of diplomatic relations between China and Japan, and Honorary Advisor was conferred on him by PUHSC and Center of Japanese Studies, Fudan University.

Eisai’s business in China started in 1991, when a joint venture named Shenyang Eisai Pharmaceutical Company was established. For better satisfying patients’ need, Eisai established a 100% owned foreign pharmaceutical company in Suzhou, 2006. Over the past two decades, Eisai China had focused on big medical institutions in big cities, promoting original medicines. In Fiscal Year 2015, sales revenue of Eisai China reached 49.3 billion JPY, increased by 20% over the previous year, and had become a driving force with high growth in Eisai Group.

Eisai’s philosophy is human health care (hhc), which has been recorded in Eisai’s Articles of Association. We aim to providing effective medicines to more patients, regardless of where they live or their income. At the 20th Anniversary of Eisai China, Eisai established Eisai (Liaoning) Pharmaceutical Company by acquiring Liaoning Tianyi Company. The acquisition marked a firm step into the low tier market. We look forward to covering small medical institutions in small cities of mainland China through generics business to make contribution to more patients by our high-quality products with affordable price.

We will stick to high-standard quality control as always, and make stable supply of high-quality products to meet varied medical needs of China’s patients.

Kaneko Norio     Chairman